Technology has the Potential to Expand Treatment Access
The incidence of cancer is growing faster than the ability of oncologists to treat it worldwide. Technology is our best chance to reach those untreated today.
Precise platforms guide precision of care
Panels, wisdom, point-of-care and workflow, four key pillars underlining the precision needed in today’s care for people with cancer. A targeted gene panel, comprehensive worldview and wisdom from oncologists, a personalized treatment plan at point-of-care, and a reduction in administrative burden.
The Story of GeneSilico
The incidence of cancer is growing worldwide. We will go from 20 million new cases in 2022 to 35 million new cases in 2050, according to The International Agency for Research on Cancer.
It is no surprise that demand for oncology services continues to grow at a rate far greater than the actual growth of the services (48% growth in demand vs. 14% growth in services; source: ASCO 2020).
Healthcare disparities are growing worldwide, as a result. For example, in India, there is one oncologist for every one million people vs. 161 in the U.S. This translates to 2,000 oncologists for 1.4 billion people.
The average oncologist in India sees 100 patients per day. When patients reach their doctor they are more often at an advanced stage of cancer. The wait for services has a consequence which can lead to lower survivability and quality of life if patients are diagnosed at later stages of their cancer. Our goal is to improve access to treatment and access to care in general. It’s a problem we all want to solve together.
GeneSilico was created to support oncologists to expand their ability to treat patients."
Brian Garsson
Chief Executive Officer / Board
GeneSilico.AI
Technology has a unique role in solving the problem, since we can assemble information needed for diagnosis and treatment more efficiently and every oncologist can benefit from the learnings of their peer network via our AI ecosystem.
Our goal is to get collectively smarter everyday to benefit the next patient. We know patients are waiting and it drives us every day.
A team designed for the solution
GeneSilico’s team is designed to be complementary to oncologists, similar to how our platform is built. We have built technology companies, scaled solutions in healthcare for some of the largest companies, and we listen to oncology leaders continually.
Our journey takes us to where the need is greatest
We are starting in India because it is a country of highly skilled oncologists and a tremendous unmet need in cancer exists. We are partnering with Omega Hospital, one of India’s leading cancer centers, based in Hyderabad, and we are starting with breast cancer as our pilot tumor type.
Breast cancer is the most common cancer in India, accounting for almost 1/3 of all female cancers.
We believe technology can help oncologists become more efficient, help them scale and reach more patients at critical times in their disease journey.
Join Us on Our Journey
At GeneSilico, we're shaping the future of precision oncology.Your expertise and passion can help achieve our vision: personalized cancer treatment for all. We look forward to hearing from you.
.jpg)